Riskpilot← Back to searchSign inGet full accessSEMSBYEN APOTEK AS
ASActiveOrg 916142161Kyrkjevegen 1, 3580 GeiloRetail sale of pharmaceutical products · NACE 4773Est. 20150 employees
Revenue 2022
NOK 0
EBITDA margin
—
-150% vs 2021
Equity ratio
-620.4%
Financial strength
Net profit 2022
NOK -92K
-231% vs 2021
| Revenue | NOK 0 | — |
| EBITDA | NOK -92K | -150% |
| Net profit | NOK -92K | -231% |
| Total assets | NOK 748K | -1% |
| Equity | NOK -4,6M | -2% |
| Employees | 0 | — |
Legal name
SEMSBYEN APOTEK AS
Org number
916142161
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
3. november 2015
Share capital
NOK 30 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Styret i fellesskap. Styrets medlemmer hver for seg. Styrets leder alene.
Company purpose
Eie og drive apotek, herunder konsulent tjenester innenfor apotekerbransjen og lege -og helserelaterte produkter, samt øvrig virksomhet i tilknytning til dette.
Address
Kyrkjevegen 1, 3580 Geilo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenue | 7 914 | 5 375 | 435 | 0 | 0 |
| Staff expenses | −1 811 | −1 537 | −54 | −0 | 6 |
| EBITDA | −475 | −911 | 95 | −37 | −92 |
| Depreciation & amort. | −86 | −86 | −29 | −0 | −0 |
| EBIT | −561 | −997 | 66 | −37 | −92 |
| Net financials | −78 | −127 | −125 | 107 | −0 |
| Profit before tax | −639 | −1 124 | −59 | 70 | −92 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −639 | −1 124 | −59 | 70 | −92 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Total assets | 1 110 | 185 | 751 | 758 | 748 |
| Equity | −3 438 | −4 562 | −4 622 | −4 551 | −4 643 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 4 549 | 4 747 | 5 372 | 5 309 | 5 392 |
| Total debt | 4 549 | 4 747 | 5 372 | 5 309 | 5 392 |
EBITDA margin
-9215100.0%
This company
15.8%
Market median
-58323518% vs market
20182022
Equity ratio
-620.4%
This company
38.2%
Market median
-1724% vs market
20182022
Return on equity
-9216300.0%
This company
18.4%
Market median
-50088687% vs market
20182022
Net profit margin
-9216300.0%
This company
8.1%
Market median
-113781581% vs market
20182022
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20182022
Debt / equity
1.16×
This company
0.62×
Market median
-87% vs market
20182022
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
MR Deputy Member | Deputy Member | 2019 – 2019 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2019 | |
| Chairman | 2019 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
PLUS PHARMACIES AS
SEMSBYEN APOTEK AS Board members of SEMSBYEN APOTEK AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Marius Remman | Deputy Member | 0 companies |
| Tom Remman | Board of Directors | 0 companies |
| Mari-Mette Aasen | Chairman | 0 companies |